VISTIN PHARMA ASA (VISTN.OL) Fundamental Analysis & Valuation

OSL:VISTN • NO0010734122

Current stock price

22 NOK
+0.5 (+2.33%)
Last:

This VISTN.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. VISTN.OL Profitability Analysis

1.1 Basic Checks

  • In the past year VISTN was profitable.
  • In the past year VISTN had a positive cash flow from operations.
  • Of the past 5 years VISTN 4 years were profitable.
  • VISTN had a positive operating cash flow in 4 of the past 5 years.
VISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFVISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • VISTN has a better Return On Assets (17.01%) than 88.46% of its industry peers.
  • Looking at the Return On Equity, with a value of 22.73%, VISTN is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
  • VISTN's Return On Invested Capital of 19.98% is amongst the best of the industry. VISTN outperforms 82.69% of its industry peers.
Industry RankSector Rank
ROA 17.01%
ROE 22.73%
ROIC 19.98%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VISTN.OL Yearly ROA, ROE, ROICVISTN.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

1.3 Margins

  • VISTN has a Profit Margin of 16.53%. This is in the better half of the industry: VISTN outperforms 61.54% of its industry peers.
  • Looking at the Operating Margin, with a value of 20.42%, VISTN is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of VISTN has grown nicely.
  • With a Gross Margin value of 66.50%, VISTN is not doing good in the industry: 63.46% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of VISTN has remained more or less at the same level.
Industry RankSector Rank
OM 20.42%
PM (TTM) 16.53%
GM 66.5%
OM growth 3YN/A
OM growth 5Y2.56%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.54%
GM growth 5Y-1.31%
VISTN.OL Yearly Profit, Operating, Gross MarginsVISTN.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. VISTN.OL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VISTN is creating value.
  • There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VISTN.OL Yearly Shares OutstandingVISTN.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
VISTN.OL Yearly Total Debt VS Total AssetsVISTN.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 7.90 indicates that VISTN is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 7.90, VISTN belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
  • There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.9
ROIC/WACC2.33
WACC8.57%
VISTN.OL Yearly LT Debt VS Equity VS FCFVISTN.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • VISTN has a Current Ratio of 2.58. This indicates that VISTN is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 2.58, VISTN belongs to the best of the industry, outperforming 80.77% of the companies in the same industry.
  • A Quick Ratio of 1.54 indicates that VISTN should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.54, VISTN is in the better half of the industry, outperforming 78.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 1.54
VISTN.OL Yearly Current Assets VS Current LiabilitesVISTN.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VISTN.OL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 19.14% over the past year.
  • The Revenue has been growing slightly by 5.41% in the past year.
  • The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)19.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.06%
Revenue 1Y (TTM)5.41%
Revenue growth 3Y16.28%
Revenue growth 5Y12.31%
Sales Q2Q%-2.25%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VISTN.OL Yearly Revenue VS EstimatesVISTN.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
VISTN.OL Yearly EPS VS EstimatesVISTN.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

3

4. VISTN.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 13.02, VISTN is valued correctly.
  • Compared to the rest of the industry, the Price/Earnings ratio of VISTN indicates a somewhat cheap valuation: VISTN is cheaper than 75.00% of the companies listed in the same industry.
  • VISTN is valuated rather cheaply when we compare the Price/Earnings ratio to 25.35, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.02
Fwd PE N/A
VISTN.OL Price Earnings VS Forward Price EarningsVISTN.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • VISTN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VISTN is cheaper than 80.77% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, VISTN is valued a bit cheaper than 78.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.73
EV/EBITDA 8.16
VISTN.OL Per share dataVISTN.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. VISTN.OL Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 6.04%, VISTN is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.95, VISTN pays a better dividend. On top of this VISTN pays more dividend than 94.23% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, VISTN pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.04%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • VISTN pays out 74.15% of its income as dividend. This is not a sustainable payout ratio.
DP74.15%
EPS Next 2YN/A
EPS Next 3YN/A
VISTN.OL Yearly Income VS Free CF VS DividendVISTN.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M
VISTN.OL Dividend Payout.VISTN.OL Dividend Payout, showing the Payout Ratio.VISTN.OL Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

VISTN.OL Fundamentals: All Metrics, Ratios and Statistics

VISTIN PHARMA ASA

OSL:VISTN (4/1/2026, 9:31:59 AM)

22

+0.5 (+2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)04-24
Inst Owners14.16%
Inst Owner ChangeN/A
Ins Owners4.89%
Ins Owner ChangeN/A
Market Cap975.48M
Revenue(TTM)452.29M
Net Income(TTM)74.75M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.04%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP74.15%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 13.02
Fwd PE N/A
P/S 2.16
P/FCF 15.73
P/OCF 12.39
P/B 2.97
P/tB 2.97
EV/EBITDA 8.16
EPS(TTM)1.69
EY7.68%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.4
FCFY6.36%
OCF(TTM)1.78
OCFY8.07%
SpS10.2
BVpS7.42
TBVpS7.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.79
Profitability
Industry RankSector Rank
ROA 17.01%
ROE 22.73%
ROCE 25.62%
ROIC 19.98%
ROICexc 20.94%
ROICexgc 20.94%
OM 20.42%
PM (TTM) 16.53%
GM 66.5%
FCFM 13.71%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y2.56%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.54%
GM growth 5Y-1.31%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 74.04%
Cap/Sales 3.69%
Interest Coverage 250
Cash Conversion 68.51%
Profit Quality 82.98%
Current Ratio 2.58
Quick Ratio 1.54
Altman-Z 7.9
F-Score7
WACC8.57%
ROIC/WACC2.33
Cap/Depr(3y)130.55%
Cap/Depr(5y)243.25%
Cap/Sales(3y)5.77%
Cap/Sales(5y)10.25%
Profit Quality(3y)116.42%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.41%
Revenue growth 3Y16.28%
Revenue growth 5Y12.31%
Sales Q2Q%-2.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.27%
EBIT growth 3YN/A
EBIT growth 5Y15.18%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.02%
OCF growth 3YN/A
OCF growth 5YN/A

VISTIN PHARMA ASA / VISTN.OL Fundamental Analysis FAQ

What is the fundamental rating for VISTN stock?

ChartMill assigns a fundamental rating of 5 / 10 to VISTN.OL.


Can you provide the valuation status for VISTIN PHARMA ASA?

ChartMill assigns a valuation rating of 3 / 10 to VISTIN PHARMA ASA (VISTN.OL). This can be considered as Overvalued.


What is the profitability of VISTN stock?

VISTIN PHARMA ASA (VISTN.OL) has a profitability rating of 5 / 10.


Can you provide the financial health for VISTN stock?

The financial health rating of VISTIN PHARMA ASA (VISTN.OL) is 8 / 10.